<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911126-0136</DOCNO><DOCID>911126-0136.</DOCID><HL>   Technology:   Genetic Therapy Inc.   Enters Into Ventures   With Unit of Sandoz</HL><DATE>11/26/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   GTII Z.SAN</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>JOINT VENTURES (JVN)LICENSING AGREEMENTS (LIC)ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>EUROPE (EU)MARYLAND (MD)NORTH AMERICA (NME)SWITZERLAND (SZ)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   GAITHERSBURG, Md. -- Genetic Therapy Inc. said it entereda broad series of collaborative agreements with a unit ofSandoz Ltd. of Switzerland to develop and commercializegene-transfer technology.   The Sandoz unit, Sandoz Pharma Ltd., in a related move,purchased 470,357 Genetic Therapy common shares for $10million, or $21.26 a share. The shares represent a 6.1% stakeand will entitle Sandoz to nominate one director to GeneticTherapy's board. Currently, there are eight directors on theboard.</LP><TEXT>   After the announcement yesterday, Genetic Therapy rose87.5 cents to $13.875 in national over-the-counter trading.   Genetic Therapy said Sandoz Pharma agreed to provide asmuch as $13.5 million over three years for as many as threeprojects; Genetic Therapy itself would contribute $1 milliona project. Sandoz Pharma also agreed to provide milestonepayments of as much as $11.5 million a product &quot;upon theoccurrence of certain events,&quot; Genetic Therapy said. Thecollaborative effort covers applications in immunology/inflammation, including asthma; cancer; and cardiovasculardisease.   In turn, Genetic Therapy said it granted Sandoz Pharma theexclusive world-wide right to use technology developed underthe agreement and to make and sell related products inexchange for royalties. Genetic Therapy noted the pactdoesn't apply to certain research areas, including geneticdiseases, where Genetic Therapy intends to develop productsitself.</TEXT></DOC>